Eledon Pharmaceuticals Appoints Jan Hillson, M.D., to its Board of Directors
Eledon Pharmaceuticals (NASDAQ: ELDN) announced the appointment of Dr. Jan Hillson to its Board of Directors. Dr. Hillson is the Senior VP of Clinical Development at Alpine Immune Sciences and brings extensive experience in immunology and rheumatology. CEO David-Alexandre Gros expressed confidence that her insights will be valuable in advancing Eledon's lead drug, AT-1501, through clinical development. AT-1501 is designed to treat autoimmune diseases, organ transplants, and ALS. The company is focused on targeting the CD40L pathway for therapeutic benefits.
- Appointment of Dr. Jan Hillson expected to bring valuable insights and expertise in immunology.
- Dr. Hillson's extensive experience enhances the leadership team as Eledon advances AT-1501.
- Potential gaps in experience or continuity may arise from the new appointment.
- -
IRVINE, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced the appointment of Jan Hillson, M.D., to the company’s Board of Directors. Dr. Hillson currently serves as Senior Vice President of Clinical Development at Alpine Immune Sciences, a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer and autoimmune and inflammatory diseases.
“I am extremely pleased that Dr. Hillson is joining our Board of Directors,” stated David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon Pharmaceuticals, Inc. “As a proven biotechnology industry leader with extensive immunology and rheumatology experience, we believe Dr. Hillson’s insights will be invaluable as we continue to advance our lead asset, AT-1501, a novel antibody targeting the CD40 ligand co-stimulatory signaling pathway, through clinical development in multiple indications.”
“It is a pleasure to join the Eledon Board of Directors at such an exciting time in the Company’s evolution,” said Dr. Hillson. “I look forward to working with the leadership team and the Board as they continue the development of AT-1501 which may have therapeutic effects in transplantation and a range of immuno-inflammatory diseases, and may help unlock a functional cure in Type 1 diabetes.”
Prior to Alpine Immune Sciences, Dr. Hillson was Senior Vice President of Drug Development for ChemoCentryx, and, before that, served as Vice President of Clinical and Translational Research at Momenta Pharmaceuticals. Earlier in her career, she served in senior roles at ZymoGenetics/Bristol Myers Squibb and Xcyte Therapies. Dr, Hillson also served as a member of the Clinical Faculty at Harvard Medical School, Assistant Professor at the University of Washington, and Head of the Department of Rheumatology at Virginia Mason Medical Center. Dr. Hillson is a licensed rheumatologist and continues to care for patients. She received her MD from Stanford School of Medicine, an MS from the California Institute of Technology, an MS in Marine Chemistry from Scripps Institute of Oceanography, and a BS from Michigan State University.
About Eledon Pharmaceuticals and AT-1501
Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company’s lead compound in development is AT-1501, an anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. AT-1501 is a humanized IgG1 antibody engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. The CD40L/CD40 pathway is widely recognized for its prominent role in immune regulation. CD40L is primarily expressed on activated CD4+ T cells, platelets and endothelial cells while the CD40 receptor is constitutively expressed on antigen presenting cells such as B cells, macrophages, and dendritic cells. By blocking CD40L and not the CD40 receptor, AT-1501 inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches. Blocking CD40L also increases polarization of CD4+ lymphocytes to Tregs, a specialized subpopulation of T cells that act to suppress an immune response, thus creating a more tolerogenic environment, which may also play a therapeutic role for autoimmune diseases and in the transplant setting. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: @Eledon_Pharma and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from clinical trials, the company’s capital resources and ability to finance planned clinical trials, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: risks relating to the safety and efficacy of our drug candidates; risks relating to clinical development timelines, including interactions with regulators and clinical sides, as well as patient enrollment; risks relating to costs of clinical trials and the sufficiency of the company’s capital resources to fund planned clinical trials; and risks associated with the impact of the ongoing coronavirus pandemic. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ significantly from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212.915.2577
Source: Eledon Pharmaceuticals
FAQ
Who is the new member of Eledon Pharmaceuticals' Board of Directors?
What experience does Dr. Jan Hillson bring to Eledon Pharmaceuticals?
What is AT-1501 and its significance?
How might Dr. Hillson's appointment impact Eledon Pharmaceuticals?
What is the primary focus of Eledon Pharmaceuticals?
